A Phase 2 Study of Nivolumab in Combination With Either Rucaparib, Docetaxel, or Enzalutamide in Men With Castration-resistant Metastatic Prostate Cancer

What is the purpose of this trial?

The purpose of this study is to determine which combination of Nivolumab plus either Rucaparib, Docetaxel, or Enzalutamide is the most effective in treating Castration-resistant Prostate Cancer that has spread



Bristol-Myers Squibb Research and Development

Start Date: 09/27/2018

End Date: 02/18/2020

Last Updated: 12/04/2018

Study HIC#: 2000022918